Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Income from Continuing Operations (2023 - 2025)

Mangoceuticals' Income from Continuing Operations history spans 3 years, with the latest figure at 2769370.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 42.12% to 2769370.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 20643455.0, a 137.08% decrease, with the full-year FY2025 number at 20643455.0, down 137.08% from a year prior.
  • Income from Continuing Operations hit 2769370.0 in Q4 2025 for Mangoceuticals, up from 7618776.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for MGRX hit a ceiling of 1799460.0 in Q3 2023 and a floor of 7618776.0 in Q3 2025.
  • Historically, Income from Continuing Operations has averaged 3213591.5 across 3 years, with a median of 2476102.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: grew 24.12% in 2024 and later tumbled 281.0% in 2025.
  • Tracing MGRX's Income from Continuing Operations over 3 years: stood at 2568047.0 in 2023, then grew by 24.12% to 1948596.0 in 2024, then tumbled by 42.12% to 2769370.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for MGRX at 2769370.0 in Q4 2025, 7618776.0 in Q3 2025, and 5415820.0 in Q2 2025.